公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 (HLX03)、贝伐珠单抗汉贝泰(HLX04)，进行合作开发，开展本地注册、生产及商业化。另外，此次合 作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共同推动 该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万港元。 ...

公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 （HLX03）、贝伐珠单抗汉贝泰（HLX04），进行合作开发，开展本地注册、生产及商业化。另外， 此次合作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共 同推动该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 智通财经APP获悉，复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万 港元。 ...

Core Insights - The company, Fuhong Hanlin, is deeply engaged in the biopharmaceutical sector, focusing on innovative strategies and solid actions to advance its development plans globally [1][2][3] Global Strategy - Fuhong Hanlin is committed to a globalization strategy, expanding its international market presence through collaborations with renowned global enterprises [1] - The establishment of a wholly-owned subsidiary in Japan allows the company to better understand local market demands and facilitate clinical development and registration of related drug candidates [1] - In Latin America, Fuhong Hanlin has successfully expanded its product coverage through partnerships with local companies, enhancing treatment options for patients and increasing its global market influence [1] Product Development - The company maintains a strong focus on product research and development, with a diverse pipeline addressing various disease treatment areas [2] - The development of the biosimilar HLX17 has gained significant attention, with the company receiving FDA approval to initiate Phase I clinical trials for treating various resected solid tumor patients by September 2025 [2] - Fuhong Hanlin emphasizes global resource integration and collaboration with domestic and international research institutions to enhance R&D efficiency and quality [2] Future Outlook - Fuhong Hanlin plans to strengthen innovation-driven initiatives, optimize global layouts, and accelerate product development processes [3] - The company aims to deepen collaborations with global partners and increase investments in R&D to bring more innovative products from the lab to clinical applications [3] - The commitment to innovation positions Fuhong Hanlin to contribute significantly to global health by providing high-quality biopharmaceuticals [3]